CA2894220A1 - Dot1l inhibitors for use in the treatment of leukemia - Google Patents

Info

Publication number

CA2894220A1

CA2894220A1 CA2894220A CA2894220A CA2894220A1 CA 2894220 A1 CA2894220 A1 CA 2894220A1 CA 2894220 A CA2894220 A CA 2894220A CA 2894220 A CA2894220 A CA 2894220A CA 2894220 A1 CA2894220 A1 CA 2894220A1

Authority

CA

Canada

Prior art keywords

cancer

amino

compound

subject

methyl

Prior art date

2012-12-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 208000032839 leukemia Diseases 0.000 title claims description 72
• 239000003112 inhibitor Substances 0.000 title abstract description 25
• 238000011282 treatment Methods 0.000 title description 65
• 150000001875 compounds Chemical class 0.000 claims abstract description 266
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 252
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 156
• 238000000034 method Methods 0.000 claims abstract description 141
• 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims abstract description 71
• 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims abstract description 70
• 230000001404 mediated effect Effects 0.000 claims abstract description 30
• 210000004027 cell Anatomy 0.000 claims description 217
• 108090000623 proteins and genes Proteins 0.000 claims description 99
• 208000024891 symptom Diseases 0.000 claims description 45
• 102100021090 Homeobox protein Hox-A9 Human genes 0.000 claims description 44
• 108010027263 homeobox protein HOXA9 Proteins 0.000 claims description 44
• 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims description 42
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 42
• 101150029107 MEIS1 gene Proteins 0.000 claims description 40
• 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 claims description 40
• 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 claims description 40
• 230000003902 lesion Effects 0.000 claims description 39
• 210000001519 tissue Anatomy 0.000 claims description 26
• 230000002068 genetic effect Effects 0.000 claims description 13
• 230000036961 partial effect Effects 0.000 claims description 13
• 210000004369 blood Anatomy 0.000 claims description 12
• 239000008280 blood Substances 0.000 claims description 12
• 230000004927 fusion Effects 0.000 claims description 12
• SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims description 11
• 210000000349 chromosome Anatomy 0.000 claims description 11
• 230000005945 translocation Effects 0.000 claims description 11
• 230000008711 chromosomal rearrangement Effects 0.000 claims description 8
• 238000012217 deletion Methods 0.000 claims description 7
• 230000037430 deletion Effects 0.000 claims description 7
• 210000002700 urine Anatomy 0.000 claims description 5
• 210000002966 serum Anatomy 0.000 claims description 4
• 210000001185 bone marrow Anatomy 0.000 claims description 3
• 210000004976 peripheral blood cell Anatomy 0.000 claims description 3
• 210000002381 plasma Anatomy 0.000 claims description 3
• 210000003296 saliva Anatomy 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 abstract description 170
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
• 230000019639 protein methylation Effects 0.000 abstract description 13
• 101100063942 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) dot-1 gene Proteins 0.000 abstract description 5
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 200
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 162
• -1 F1t3 Proteins 0.000 description 153
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 138
• 125000005843 halogen group Chemical group 0.000 description 127
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 126
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 111
• 208000035475 disorder Diseases 0.000 description 109
• 125000005605 benzo group Chemical group 0.000 description 99
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 97
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 93
• 125000003545 alkoxy group Chemical group 0.000 description 91
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 91
• 230000002062 proliferating effect Effects 0.000 description 87
• 125000001424 substituent group Chemical group 0.000 description 73
• 125000004093 cyano group Chemical group *C#N 0.000 description 67
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 66
• 208000026310 Breast neoplasm Diseases 0.000 description 65
• 125000000041 C6-C10 aryl group Chemical group 0.000 description 64
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 63
• 230000000694 effects Effects 0.000 description 63
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 58
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 58
• 206010006187 Breast cancer Diseases 0.000 description 57
• 230000002829 reductive effect Effects 0.000 description 57
• 150000003839 salts Chemical class 0.000 description 55
• 238000005481 NMR spectroscopy Methods 0.000 description 52
• 102000004169 proteins and genes Human genes 0.000 description 52
• 125000003118 aryl group Chemical group 0.000 description 50
• 235000018102 proteins Nutrition 0.000 description 50
• 239000000126 substance Substances 0.000 description 50
• 241001024304 Mino Species 0.000 description 45
• 201000010099 disease Diseases 0.000 description 45
• 239000012453 solvate Substances 0.000 description 45
• 239000000651 prodrug Substances 0.000 description 40
• 229940002612 prodrug Drugs 0.000 description 40
• 150000002009 diols Chemical class 0.000 description 39
• 239000002207 metabolite Substances 0.000 description 39
• 239000000203 mixture Substances 0.000 description 39
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 37
• 125000000217 alkyl group Chemical group 0.000 description 36
• 108010033040 Histones Proteins 0.000 description 29
• 239000000523 sample Substances 0.000 description 28
• 210000000481 breast Anatomy 0.000 description 26
• 125000000304 alkynyl group Chemical group 0.000 description 25
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
• 125000003342 alkenyl group Chemical group 0.000 description 24
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 24
• 208000006994 Precancerous Conditions Diseases 0.000 description 23
• 125000004432 carbon atom Chemical group C* 0.000 description 23
• 230000014509 gene expression Effects 0.000 description 23
• 108020004999 messenger RNA Proteins 0.000 description 23
• 230000011987 methylation Effects 0.000 description 23
• 238000007069 methylation reaction Methods 0.000 description 23
• 229910052799 carbon Inorganic materials 0.000 description 22
• 230000007423 decrease Effects 0.000 description 22
• 230000004083 survival effect Effects 0.000 description 21
• 125000004429 atom Chemical group 0.000 description 20
• 210000004072 lung Anatomy 0.000 description 20
• 229910052757 nitrogen Inorganic materials 0.000 description 20
• 238000003556 assay Methods 0.000 description 19
• 125000005842 heteroatom Chemical group 0.000 description 19
• 210000003491 skin Anatomy 0.000 description 19
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 18
• 210000001072 colon Anatomy 0.000 description 18
• 125000001072 heteroaryl group Chemical group 0.000 description 18
• 125000004433 nitrogen atom Chemical group N* 0.000 description 18
• 125000003282 alkyl amino group Chemical group 0.000 description 17
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
• 208000029742 colonic neoplasm Diseases 0.000 description 17
• 230000006870 function Effects 0.000 description 17
• 238000005259 measurement Methods 0.000 description 17
• 102000004190 Enzymes Human genes 0.000 description 16
• 108090000790 Enzymes Proteins 0.000 description 16
• 230000012820 cell cycle checkpoint Effects 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 208000020816 lung neoplasm Diseases 0.000 description 16
• 229910052717 sulfur Inorganic materials 0.000 description 16
• 206010009944 Colon cancer Diseases 0.000 description 15
• 125000002877 alkyl aryl group Chemical group 0.000 description 15
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 15
• 230000030833 cell death Effects 0.000 description 15
• 125000000623 heterocyclic group Chemical group 0.000 description 15
• 238000002560 therapeutic procedure Methods 0.000 description 15
• 241000282414 Homo sapiens Species 0.000 description 14
• 201000005202 lung cancer Diseases 0.000 description 14
• 206010061289 metastatic neoplasm Diseases 0.000 description 14
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
• SSYDTHANSGMJTP-UHFFFAOYSA-N oxolane-3,4-diol Chemical compound OC1COCC1O SSYDTHANSGMJTP-UHFFFAOYSA-N 0.000 description 14
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 13
• 241000927721 Tritia Species 0.000 description 13
• 238000006243 chemical reaction Methods 0.000 description 13
• 230000001394 metastastic effect Effects 0.000 description 13
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• 206010025323 Lymphomas Diseases 0.000 description 12
• 125000005110 aryl thio group Chemical group 0.000 description 12
• 239000003937 drug carrier Substances 0.000 description 12
• 230000012010 growth Effects 0.000 description 12
• 210000000496 pancreas Anatomy 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
• 239000013078 crystal Substances 0.000 description 11
• 150000002148 esters Chemical class 0.000 description 11
• 206010020718 hyperplasia Diseases 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 10
• 150000001721 carbon Chemical group 0.000 description 10
• 230000004663 cell proliferation Effects 0.000 description 10
• 125000000753 cycloalkyl group Chemical group 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 150000007523 nucleic acids Chemical group 0.000 description 10
• 210000000056 organ Anatomy 0.000 description 10
• 210000001672 ovary Anatomy 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 102000004196 processed proteins & peptides Human genes 0.000 description 10
• 210000002307 prostate Anatomy 0.000 description 10
• 238000003419 tautomerization reaction Methods 0.000 description 10
• 108020004414 DNA Proteins 0.000 description 9
• 102000006947 Histones Human genes 0.000 description 9
• 206010054949 Metaplasia Diseases 0.000 description 9
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 9
• 230000002159 abnormal effect Effects 0.000 description 9
• 125000004442 acylamino group Chemical group 0.000 description 9
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 9
• 125000004414 alkyl thio group Chemical group 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
• XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 9
• 125000004663 dialkyl amino group Chemical group 0.000 description 9
• 229910052736 halogen Inorganic materials 0.000 description 9
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
• 201000001441 melanoma Diseases 0.000 description 9
• 230000015689 metaplastic ossification Effects 0.000 description 9
• 208000008443 pancreatic carcinoma Diseases 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 8
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 8
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 8
• 150000001204 N-oxides Chemical class 0.000 description 8
• 229910019142 PO4 Inorganic materials 0.000 description 8
• 108700040121 Protein Methyltransferases Proteins 0.000 description 8
• 102000055027 Protein Methyltransferases Human genes 0.000 description 8
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 8
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
• 125000004947 alkyl aryl amino group Chemical group 0.000 description 8
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 8
• 125000001769 aryl amino group Chemical group 0.000 description 8
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 8
• 125000004104 aryloxy group Chemical group 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 8
• 150000007942 carboxylates Chemical class 0.000 description 8
• 125000004986 diarylamino group Chemical group 0.000 description 8
• 150000002367 halogens Chemical class 0.000 description 8
• 201000005787 hematologic cancer Diseases 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
• 201000002528 pancreatic cancer Diseases 0.000 description 8
• 235000021317 phosphate Nutrition 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 229910052702 rhenium Inorganic materials 0.000 description 8
• 229910052703 rhodium Inorganic materials 0.000 description 8
• 239000000758 substrate Substances 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 210000004881 tumor cell Anatomy 0.000 description 8
• 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 7
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 7
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 7
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
• 206010058314 Dysplasia Diseases 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 7
• 229960001570 ademetionine Drugs 0.000 description 7
• 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 7
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 7
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 7
• 125000004644 alkyl sulfinyl group Chemical group 0.000 description 7
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 7
• 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 7
• 125000005129 aryl carbonyl group Chemical group 0.000 description 7
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 7
• 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 7
• 229910002091 carbon monoxide Inorganic materials 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 230000001973 epigenetic effect Effects 0.000 description 7
• 230000002489 hematologic effect Effects 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 210000001165 lymph node Anatomy 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
• 239000010452 phosphate Substances 0.000 description 7
• 238000003752 polymerase chain reaction Methods 0.000 description 7
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 7
• 125000004434 sulfur atom Chemical group 0.000 description 7
• 150000003467 sulfuric acid derivatives Chemical group 0.000 description 7
• 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 6
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
• 102000011787 Histone Methyltransferases Human genes 0.000 description 6
• 108010036115 Histone Methyltransferases Proteins 0.000 description 6
• 208000008839 Kidney Neoplasms Diseases 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 206010038389 Renal cancer Diseases 0.000 description 6
• 206010039491 Sarcoma Diseases 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 125000000524 functional group Chemical group 0.000 description 6
• 125000004438 haloalkoxy group Chemical group 0.000 description 6
• 201000010982 kidney cancer Diseases 0.000 description 6
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 6
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
• 125000001624 naphthyl group Chemical group 0.000 description 6
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
• 125000003396 thiol group Chemical group [H]S* 0.000 description 6
• 108010077544 Chromatin Proteins 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 206010060862 Prostate cancer Diseases 0.000 description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 210000003483 chromatin Anatomy 0.000 description 5
• LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 description 5
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 210000005096 hematological system Anatomy 0.000 description 5
• 230000002962 histologic effect Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 150000002825 nitriles Chemical class 0.000 description 5
• 125000004043 oxo group Chemical group O=* 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 150000003212 purines Chemical class 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 238000009097 single-agent therapy Methods 0.000 description 5
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 4
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 102100033636 Histone H3.2 Human genes 0.000 description 4
• 208000017604 Hodgkin disease Diseases 0.000 description 4
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
• 208000034578 Multiple myelomas Diseases 0.000 description 4
• 208000012902 Nervous system disease Diseases 0.000 description 4
• 108010047956 Nucleosomes Proteins 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 206010037660 Pyrexia Diseases 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• 230000018199 S phase Effects 0.000 description 4
• 208000000453 Skin Neoplasms Diseases 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
• 125000002619 bicyclic group Chemical group 0.000 description 4
• 201000005389 breast carcinoma in situ Diseases 0.000 description 4
• 239000004202 carbamide Substances 0.000 description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 description 4
• 208000002458 carcinoid tumor Diseases 0.000 description 4
• 230000032823 cell division Effects 0.000 description 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 102000015694 estrogen receptors Human genes 0.000 description 4
• 108010038795 estrogen receptors Proteins 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 239000002777 nucleoside Substances 0.000 description 4
• 210000001623 nucleosome Anatomy 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 102000003998 progesterone receptors Human genes 0.000 description 4
• 108090000468 progesterone receptors Proteins 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 230000004043 responsiveness Effects 0.000 description 4
• 210000005005 sentinel lymph node Anatomy 0.000 description 4
• 201000000849 skin cancer Diseases 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 210000002784 stomach Anatomy 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 208000011580 syndromic disease Diseases 0.000 description 4
• 125000001544 thienyl group Chemical group 0.000 description 4
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 210000003932 urinary bladder Anatomy 0.000 description 4
• 201000005112 urinary bladder cancer Diseases 0.000 description 4
• 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
• PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 206010069754 Acquired gene mutation Diseases 0.000 description 3
• 108700020463 BRCA1 Proteins 0.000 description 3
• 102000036365 BRCA1 Human genes 0.000 description 3
• 101150072950 BRCA1 gene Proteins 0.000 description 3
• 102000052609 BRCA2 Human genes 0.000 description 3
• 108700020462 BRCA2 Proteins 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 206010004593 Bile duct cancer Diseases 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 101150008921 Brca2 gene Proteins 0.000 description 3
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 101150029707 ERBB2 gene Proteins 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 208000034951 Genetic Translocation Diseases 0.000 description 3
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 101000718497 Homo sapiens Protein AF-10 Proteins 0.000 description 3
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
• 108010044467 Isoenzymes Proteins 0.000 description 3
• 208000027747 Kennedy disease Diseases 0.000 description 3
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 208000010191 Osteitis Deformans Diseases 0.000 description 3
• 208000027868 Paget disease Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102100026286 Protein AF-10 Human genes 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 229910019567 Re Re Inorganic materials 0.000 description 3
• 206010070308 Refractory cancer Diseases 0.000 description 3
• 108700039010 SET domains Proteins 0.000 description 3
• 102000051614 SET domains Human genes 0.000 description 3
• 206010040070 Septic Shock Diseases 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 3
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 238000004166 bioassay Methods 0.000 description 3
• 230000008827 biological function Effects 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• 238000012258 culturing Methods 0.000 description 3
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 201000009277 hairy cell leukemia Diseases 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 238000013537 high throughput screening Methods 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 3
• 208000027202 mammary Paget disease Diseases 0.000 description 3
• 238000007726 management method Methods 0.000 description 3
• 201000006512 mast cell neoplasm Diseases 0.000 description 3
• HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 230000017074 necrotic cell death Effects 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 238000002953 preparative HPLC Methods 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 3
• 230000035945 sensitivity Effects 0.000 description 3
• 239000002356 single layer Substances 0.000 description 3
• 230000037439 somatic mutation Effects 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 238000004808 supercritical fluid chromatography Methods 0.000 description 3
• 238000010189 synthetic method Methods 0.000 description 3
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 231100001274 therapeutic index Toxicity 0.000 description 3
• 230000008719 thickening Effects 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 208000008732 thymoma Diseases 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 3
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
• 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003571 Astrocytoma Diseases 0.000 description 2
• 102000007371 Ataxin-3 Human genes 0.000 description 2
• 102000007368 Ataxin-7 Human genes 0.000 description 2
• 108010032953 Ataxin-7 Proteins 0.000 description 2
• 206010006189 Breast cancer in situ Diseases 0.000 description 2
• 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
• 208000035865 Chronic mast cell leukemia Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010011224 Cough Diseases 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
• 206010013952 Dysphonia Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• 208000000321 Gardner Syndrome Diseases 0.000 description 2
• 208000021309 Germ cell tumor Diseases 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
• 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
• 208000010473 Hoarseness Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000915806 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Proteins 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• 206010061252 Intraocular melanoma Diseases 0.000 description 2
• 206010023126 Jaundice Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
• 201000005027 Lynch syndrome Diseases 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 208000000172 Medulloblastoma Diseases 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 206010027406 Mesothelioma Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 102100033813 Protein ENL Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 238000011529 RT qPCR Methods 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 102100029014 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform Human genes 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 201000005969 Uveal melanoma Diseases 0.000 description 2
• 208000000260 Warts Diseases 0.000 description 2
• GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 150000008064 anhydrides Chemical class 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 125000003435 aroyl group Chemical group 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 208000019493 atypical carcinoid tumor Diseases 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
• 150000001556 benzimidazoles Chemical class 0.000 description 2
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000003714 breast lobular carcinoma Diseases 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 238000003570 cell viability assay Methods 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 201000007455 central nervous system cancer Diseases 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 201000002797 childhood leukemia Diseases 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
• VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 description 2
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 231100000517 death Toxicity 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 201000006549 dyspepsia Diseases 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 125000004441 haloalkylsulfonyl group Chemical group 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000003119 immunoblot Methods 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 208000024312 invasive carcinoma Diseases 0.000 description 2
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 201000008632 juvenile polyposis syndrome Diseases 0.000 description 2
• 125000000468 ketone group Chemical group 0.000 description 2
• 208000003849 large cell carcinoma Diseases 0.000 description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 201000011059 lobular neoplasia Diseases 0.000 description 2
• 210000005265 lung cell Anatomy 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 230000027939 micturition Effects 0.000 description 2
• 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 2
• 230000011278 mitosis Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 201000008106 ocular cancer Diseases 0.000 description 2
• 201000002575 ocular melanoma Diseases 0.000 description 2
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 201000009612 pediatric lymphoma Diseases 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 238000012746 preparative thin layer chromatography Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 201000010153 skin papilloma Diseases 0.000 description 2
• 208000000649 small cell carcinoma Diseases 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000000779 smoke Substances 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 125000005415 substituted alkoxy group Chemical group 0.000 description 2
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
• 230000009747 swallowing Effects 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
• 150000003536 tetrazoles Chemical group 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 125000004001 thioalkyl group Chemical group 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 208000037965 uterine sarcoma Diseases 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
• 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
• 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• 150000000180 1,2-diols Chemical class 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
• DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
• 125000005955 1H-indazolyl group Chemical group 0.000 description 1
• KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• PCJFEVUKVKQSSL-UHFFFAOYSA-N 2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N=CNO1 PCJFEVUKVKQSSL-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
• PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 102100024379 AF4/FMR2 family member 1 Human genes 0.000 description 1
• 208000037068 Abnormal Karyotype Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 208000004804 Adenomatous Polyps Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 206010060971 Astrocytoma malignant Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 206010057687 Bloody discharge Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 206010072813 Breast angiosarcoma Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical class CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010071161 Colon dysplasia Diseases 0.000 description 1
• 208000019399 Colonic disease Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• 238000012287 DNA Binding Assay Methods 0.000 description 1
• 101150001740 DOT1L gene Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
• 206010016100 Faeces discoloured Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 208000033640 Hereditary breast cancer Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 102000008157 Histone Demethylases Human genes 0.000 description 1
• 108010074870 Histone Demethylases Proteins 0.000 description 1
• 102100039869 Histone H2B type F-S Human genes 0.000 description 1
• 108010016918 Histone-Lysine N-Methyltransferase Proteins 0.000 description 1
• 102000000581 Histone-lysine N-methyltransferase Human genes 0.000 description 1
• 101710203574 Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 208000003351 Melanosis Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 206010027407 Mesothelioma malignant Diseases 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 101100513046 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) eth-1 gene Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108010066154 Nuclear Export Signals Proteins 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102100039686 Protein AF-9 Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 241000508269 Psidium Species 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 101000902133 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Histone-lysine N-methyltransferase, H3 lysine-9 specific Proteins 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 208000004760 Tenosynovitis Diseases 0.000 description 1
• 208000035199 Tetraploidy Diseases 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 206010062129 Tongue neoplasm Diseases 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 208000026487 Triploidy Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 206010046788 Uterine haemorrhage Diseases 0.000 description 1
• 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
• SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
• 231100000071 abnormal chromosome number Toxicity 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 238000003916 acid precipitation Methods 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 1
• 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000005001 aminoaryl group Chemical group 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 210000002255 anal canal Anatomy 0.000 description 1
• 230000003322 aneuploid effect Effects 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
• 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
• 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
• 208000019804 backache Diseases 0.000 description 1
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000005512 benztetrazolyl group Chemical group 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 230000008238 biochemical pathway Effects 0.000 description 1
• 230000009287 biochemical signal transduction Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 208000019664 bone resorption disease Diseases 0.000 description 1
• 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 201000009613 breast lymphoma Diseases 0.000 description 1
• 208000029610 breast phyllodes tumor Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 125000004623 carbolinyl group Chemical group 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 208000025188 carcinoma of pharynx Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000013626 chemical specie Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 201000004677 childhood cerebellar astrocytic neoplasm Diseases 0.000 description 1
• 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000000749 co-immunoprecipitation Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• GFBLFDSCAKHHGX-UHFFFAOYSA-N cyclobutanecarbonitrile Chemical compound N#CC1CCC1 GFBLFDSCAKHHGX-UHFFFAOYSA-N 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000008406 drug-drug interaction Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000005081 epithelial layer Anatomy 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 230000010856 establishment of protein localization Effects 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019439 ethyl acetate Nutrition 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000000105 evaporative light scattering detection Methods 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000010195 expression analysis Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000006650 fundamental cellular process Effects 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 210000003976 gap junction Anatomy 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000036433 growing body Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000007773 growth pattern Effects 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 150000002390 heteroarenes Chemical class 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 238000012203 high throughput assay Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 150000004680 hydrogen peroxides Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 208000000069 hyperpigmentation Diseases 0.000 description 1
• 230000003810 hyperpigmentation Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000010820 immunofluorescence microscopy Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 125000004926 indolenyl group Chemical group 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000005438 isoindazolyl group Chemical group 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 230000007803 itching Effects 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000002122 leukaemogenic effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 210000001853 liver microsome Anatomy 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 208000019420 lymphoid neoplasm Diseases 0.000 description 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
• 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 208000029565 malignant colon neoplasm Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 201000011614 malignant glioma Diseases 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 238000003159 mammalian two-hybrid assay Methods 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000000716 merkel cell Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
• 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 108091005592 methylated proteins Proteins 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 208000004707 mucinous cystadenoma Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 230000017095 negative regulation of cell growth Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 201000011682 nervous system cancer Diseases 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 238000007481 next generation sequencing Methods 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 210000002445 nipple Anatomy 0.000 description 1
• 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 201000005443 oral cavity cancer Diseases 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
• 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 208000002820 pancreatoblastoma Diseases 0.000 description 1
• 208000030314 papillary cystic neoplasm Diseases 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000004932 phenoxathinyl group Chemical group 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 125000004928 piperidonyl group Chemical group 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 108010040003 polyglutamine Proteins 0.000 description 1
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000003476 primary myelofibrosis Diseases 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
• 238000003571 reporter gene assay Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 238000007480 sanger sequencing Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 208000005893 serous cystadenoma Diseases 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 230000025185 skeletal muscle atrophy Effects 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 201000010700 sporadic breast cancer Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000005556 structure-activity relationship Methods 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 125000004426 substituted alkynyl group Chemical group 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 1
• 229930192474 thiophene Chemical group 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 150000003852 triazoles Chemical group 0.000 description 1
• 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
• 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 201000009825 uterine corpus cancer Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 210000000239 visual pathway Anatomy 0.000 description 1
• 230000004400 visual pathway Effects 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 238000003158 yeast two-hybrid assay Methods 0.000 description 1
• 238000004383 yellowing Methods 0.000 description 1